HC Wainwright Has Pessimistic Outlook of ARWR Q2 Earnings

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Equities research analysts at HC Wainwright dropped their Q2 2026 EPS estimates for Arrowhead Pharmaceuticals in a research report issued on Tuesday, February 10th. HC Wainwright analyst P. Trucchio now expects that the biotechnology company will post earnings per share of ($0.98) for the quarter, down from their previous forecast of ($0.97). HC Wainwright currently has a “Buy” rating and a $100.00 price target on the stock. The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Arrowhead Pharmaceuticals’ Q3 2026 earnings at ($1.02) EPS, Q4 2026 earnings at ($1.03) EPS, FY2026 earnings at ($2.83) EPS, Q1 2027 earnings at ($1.03) EPS, Q2 2027 earnings at ($1.24) EPS, Q3 2027 earnings at ($1.25) EPS, Q4 2027 earnings at $0.13 EPS, FY2027 earnings at ($3.36) EPS, FY2028 earnings at ($3.16) EPS, FY2029 earnings at ($1.05) EPS and FY2030 earnings at $3.08 EPS.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its earnings results on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.60 by ($0.38). Arrowhead Pharmaceuticals had a return on equity of 35.64% and a net margin of 18.54%.The company had revenue of $264.03 million for the quarter, compared to analyst estimates of $225.66 million. During the same quarter in the previous year, the company posted ($1.39) earnings per share. The company’s quarterly revenue was up 10461.3% compared to the same quarter last year.

A number of other analysts also recently commented on the company. Royal Bank Of Canada boosted their target price on Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the stock an “outperform” rating in a research report on Thursday, December 11th. Piper Sandler reaffirmed an “overweight” rating and set a $110.00 price target (up previously from $100.00) on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, January 13th. Morgan Stanley increased their price objective on shares of Arrowhead Pharmaceuticals from $48.00 to $81.00 and gave the company an “equal weight” rating in a research note on Wednesday, January 7th. Chardan Capital lifted their target price on shares of Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. Finally, The Goldman Sachs Group upped their price target on shares of Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the company a “neutral” rating in a report on Wednesday, January 7th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $81.67.

Arrowhead Pharmaceuticals Stock Performance

ARWR opened at $61.55 on Thursday. The stock has a market cap of $8.62 billion, a P/E ratio of 40.23 and a beta of 1.21. The company has a debt-to-equity ratio of 0.29, a current ratio of 3.38 and a quick ratio of 3.38. The stock’s 50 day simple moving average is $67.02 and its 200 day simple moving average is $44.60. Arrowhead Pharmaceuticals has a 1-year low of $9.57 and a 1-year high of $76.76.

Insider Activity

In other Arrowhead Pharmaceuticals news, insider James C. Hamilton sold 40,164 shares of the company’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $63.11, for a total value of $2,534,750.04. Following the transaction, the insider directly owned 171,958 shares in the company, valued at approximately $10,852,269.38. This represents a 18.93% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Christopher Richard Anzalone sold 130,000 shares of Arrowhead Pharmaceuticals stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $68.85, for a total transaction of $8,950,500.00. Following the sale, the chief executive officer owned 3,971,255 shares of the company’s stock, valued at approximately $273,420,906.75. This trade represents a 3.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 510,836 shares of company stock worth $33,603,060. Company insiders own 3.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. lifted its holdings in shares of Arrowhead Pharmaceuticals by 3.3% during the 3rd quarter. Vanguard Group Inc. now owns 16,035,870 shares of the biotechnology company’s stock worth $553,077,000 after acquiring an additional 510,798 shares during the period. Avoro Capital Advisors LLC increased its position in Arrowhead Pharmaceuticals by 2.8% during the third quarter. Avoro Capital Advisors LLC now owns 10,900,000 shares of the biotechnology company’s stock worth $375,941,000 after purchasing an additional 300,000 shares during the last quarter. Geode Capital Management LLC increased its position in Arrowhead Pharmaceuticals by 4.3% during the fourth quarter. Geode Capital Management LLC now owns 3,264,963 shares of the biotechnology company’s stock worth $216,799,000 after purchasing an additional 133,921 shares during the last quarter. Marshall Wace LLP raised its stake in Arrowhead Pharmaceuticals by 3,507.8% during the second quarter. Marshall Wace LLP now owns 2,155,998 shares of the biotechnology company’s stock worth $34,065,000 after purchasing an additional 2,096,238 shares during the period. Finally, Arrowstreet Capital Limited Partnership boosted its holdings in shares of Arrowhead Pharmaceuticals by 3,142.5% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,081,689 shares of the biotechnology company’s stock valued at $71,797,000 after purchasing an additional 2,017,489 shares during the last quarter. Institutional investors and hedge funds own 62.61% of the company’s stock.

Key Stories Impacting Arrowhead Pharmaceuticals

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and a $100 price target on ARWR, reiterating bullish conviction (the target implies substantial upside vs. the current level). HC Wainwright Reaffirms Buy Rating for Arrowhead Pharmaceuticals
• Positive Sentiment: The same HC Wainwright note raised several medium‑ and long‑range EPS forecasts (examples: Q4 2027 moved to +$0.13; FY2027, FY2028 and FY2030 were nudged toward less negative or positive territory, FY2030 to $3.08), implying a constructive multi‑year revenue/profit trajectory that supports the $100 target. MarketBeat ARWR analyst updates
• Positive Sentiment: HC Wainwright also upgraded several quarterly estimates (e.g., Q3 and Q4 2026 and Q3 2027 were revised higher), which reduces near‑term downside in their model and reflects improving operating momentum in projected quarters. MarketBeat ARWR analyst updates
• Neutral Sentiment: Company product update: coverage notes point to a “strong start” for REDEMPLO commercialization (early revenue signal that could validate forecasts if sustained). This is encouraging but preliminary—monitor upcoming sales cadence and guidance for impact. ARWR: Strong Start for REDEMPLO Commercialization
• Neutral Sentiment: Reported short‑interest entries show zero shares/0 days-to-cover in the feed (likely a data artifact). That reading does not provide reliable evidence of crowd positioning; treat as neutral until clearer reporting.
• Negative Sentiment: Offsetting the positives, HC Wainwright trimmed FY2026 EPS significantly (to -$2.83 from -$2.03) and lowered a few near‑term quarterly forecasts (Q1/Q2 2027 nudged down), which implies a weaker near‑term profit profile than previously modeled and may pressure the stock while investors re‑assess short‑term guidance. MarketBeat ARWR analyst updates

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.